% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Janssen:290075,
author = {M. Janssen and A. Leo and C. Wolf and M. Stenzinger and M.
Bartenschlager and J. Brandt and S. Sauer and M. Schmitt and
P. Dreger and R. F. Schlenk$^*$ and C. M. Denkinger and C.
Müller-Tidow},
title = {{T}reatment of chronic {COVID}-19 with
convalescent/postvaccination plasma in patients with
hematologic malignancies.},
journal = {International journal of cancer},
volume = {155},
number = {4},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2024-00974},
pages = {618-626},
year = {2024},
note = {2024 Aug 15;155(4):618-626},
abstract = {Immunocompromised patients are at high risk to fail
clearance of SARS-CoV-2. Prolonged COVID-19 constitutes a
health risk and a management problem as cancer treatments
often have to be disrupted. As SARS-CoV-2 evolves, new
variants of concern have emerged that evade available
monoclonal antibodies. Moreover, antiviral therapy promotes
SARS-CoV-2 escape mutations, particularly in
immunocompromised patients. These patients frequently suffer
from prolonged infection. No successful treatment has been
established for persistent COVID-19 infection. Here, we
report on a series of 21 immunocompromised patients with
COVID-19-most of them hematologic malignancies-treated with
plasma obtained from recently convalescent or vaccinated
donors or a combination thereof. Repeated dosing of
SARS-CoV-2-antibody-containing plasma could clear SARS-CoV-2
infection in 16 out of 21 immunocompromised patients even if
COVID-19-specific treatments failed to induce sustained
viral clearance or to improve clinical course of SARS-CoV-2
infection. Ten patients were major responders defined as an
increase delta(d)Ct of > = 5 after the first administration
of convalescent and/or vaccinated plasma (C/VP). On average,
SARS-CoV-2 PCR Ct values increased from a median value of
22.55 (IQR = 19.10-24.25) to a median value of 29.57 (IQR =
27.55-34.63; p = <.0001) in the major response subgroup.
Furthermore, when treated a second time with C/VP, even 4
out of 5 of the initial nonresponders showed an increase in
Ct-values from a median value of 23.13 (IQR = 17.75-28.05)
to a median value of 32.79 (IQR = 31.75-33.75; p = .013).
Our results suggest that C/VP could be a feasible treatment
of COVID-19 infection in patients with hematologic
malignancies who did not respond to antiviral treatment.},
keywords = {COVID‐19 (Other) / SARS‐CoV‐2‐antibody containing
plasma (Other) / prolonged SARS‐CoV‐2 infection (Other)},
cin = {W010},
ddc = {610},
cid = {I:(DE-He78)W010-20160331},
pnm = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
pid = {G:(DE-HGF)POF4-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38721724},
doi = {10.1002/ijc.34988},
url = {https://inrepo02.dkfz.de/record/290075},
}